VIR News and Press, Vir Biotechnology Inc. From 11/03/23

2023-11-03 15:00:40 ET More on the markets SPY: From Bullish To Bearish - Why The Bears Could Be Right This Time (Rating Downgrade) My View Of The S&P 500 November 2023 Edition (Technical Analysis) Famous Chart Pattern Returns To Life Six bullish stocks t...

Vir Biotechnology Inc. (VIR) is expected to report $-1.21 for Q3 2023

2023-11-02 21:42:06 ET Vir Biotechnology, Inc. (VIR) Q3 2023 Results Conference Call November 02, 2023 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Ph...

2023-11-02 16:33:24 ET More on Vir Biotechnology Vir Biotechnology: A Beaten Up Biotech With A Large Margin Of Safety Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity Vir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Pres...

– Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials – – Company expanding strategic focus to autoimmune diseases and immuno-oncology – – Jennifer Towne, Ph.D., appointed as Executive...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company’s research function from basic research through scale-...

2023-10-19 08:55:56 ET Summary Vir Biotechnology, Inc. has a broad pipeline of drug candidates, with most at the Phase 2 clinical stage, providing potential upside. The company's valuation is extremely depressed, with its market cap at a 40% discount to its cash on hand, indicatin...

2023-10-16 17:25:11 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +6% . CrossFirst Bankshares ( CFB ) +4% . Iris Energy  ( IREN ) +4% . Vir Biotechnology ( VIR ) +3% . Service Properties Trust ( SVC ) +3% . Losers: NetSco...

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4 ...

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association ...